AbbVie (NYSE:ABBV) announced today positive results from a late-stage clinical trial evaluating its experimental drug, tavapadon, for the treatment of early Parkinson's disease.
The trial, which studied two doses of tavapadon as a monotherapy, demonstrated a statistically significant improvement in patients compared to placebo.
The improvement was measured using a rating scale that assesses various aspects of the disease.
Tavapadon, if approved, could offer a new treatment option for Parkinson's disease, a progressive neurological disorder characterized by tremors, stiffness, and difficulty walking.
The drug is being developed as a once-daily oral medication.
AbbVie acquired the rights to tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics.
The positive results from this trial mark a significant milestone in the development of the drug and bring AbbVie closer to potentially offering a new treatment option for patients with Parkinson's disease.